0001104659-22-103155.txt : 20220927 0001104659-22-103155.hdr.sgml : 20220927 20220927081624 ACCESSION NUMBER: 0001104659-22-103155 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220927 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 221267387 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 8-K 1 tm2226615d1_8k.htm FORM 8-K
0000894158 false 0000894158 2022-09-27 2022-09-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 27, 2022

 

SYNTHETIC BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-12584   13-3808303

(State or other jurisdiction of

incorporation)

   (Commission File No.)  

(IRS Employer Identification

No.)

 

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

 

(301) 417-4364

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share SYN NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

  

Item 7.01.   Regulation FD Disclosure.

 

On September 27, 2022, Synthetic Biologics, Inc. (the “Company”) issued a press release announcing positive outcome from the Data and Safety Monitoring Committee (“DSMC”) review of results from the first Cohort of the Company’s Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

 

The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

 

Item 8.01.   Other Events. 

 

On September 27, 2022, the Company issued a press release announcing positive outcome from the DSMC review of results from the first Cohort of the Company’s Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

 

Key data and conclusions disclosed in the press release include:

 

Cohort 1 enrolled 19 patients who received at least 1 dose of study drug (SYN-004 or Placebo randomized 2:1). Sixteen patients received at least one dose of intravenous (IV) meropenem and 12 of these patients completed sufficient doses of IV meropenem to be evaluable towards the study endpoints. The study is on-going and remains blinded; however, key findings from blinded data for Cohort 1 are included below:

 

·Adverse events (AEs) and serious adverse events (SAEs) observed in Cohort 1 were typical of those observed in allo-HCT patients and no AEs or SAEs were determined to be related to study drug treatment by the investigators.
oA total of 13 SAEs were reported among 10 patients, with the most common SAE being infections and infestations including sepsis.
oOne patient died 14 days after the last dose of study drug (within the 30-day reporting period) due to sepsis that was not related to study drug.
·Consistent with previous studies of SYN-004 in healthy volunteers, SYN-004 was not observed in blood samples from the majority of the evaluable patients.
oA total of 3 plasma samples (~2% of all analyzed samples) had low but quantifiable levels of SYN-004 using a sensitive ECL assay.
oNone of the 3 ECL positive plasma samples was found to contain active SYN-004 using a functional enzyme activity assay.
·Meropenem pharmacokinetics were as expected for this patient population.

 

Based on a review of the safety and pharmacokinetic data, the DSMC has recommended that the study may proceed to enroll Cohort 2 in which study drug (SYN-004 or Placebo) will be administered in combination with the IV beta-lactam antibiotic piperacillin/tazobactam.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits.

 

Exhibit
Number		   Description
99.1   Press Release issued by Synthetic Biologics, Inc., dated September 27, 2022
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 27, 2022 SYNTHETIC BIOLOGICS, INC.
       
  By: /s/ Steven A. Shallcross
    Name: Steven A. Shallcross
    Title:

Chief Executive Officer and Chief Financial Officer

 

 

 

 EX-99.1 2 tm2226615d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

 

- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 -

 

Rockville, MD, September 27, 2022 – Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

 

Cohort 1 enrolled 19 patients who received at least 1 dose of study drug (SYN-004 or Placebo randomized 2:1). Sixteen patients received at least one dose of intravenous (IV) meropenem and 12 of these patients completed sufficient doses of IV meropenem to be evaluable towards the study endpoints. The study is on-going and remains blinded; however, key findings from blinded data for Cohort 1 are included below:

 

·Adverse events (AEs) and serious adverse events (SAEs) observed in Cohort 1 were typical of those observed in allo-HCT patients and no AEs or SAEs were determined to be related to study drug treatment by the investigators.
oA total of 13 SAEs were reported among 10 patients, with the most common SAE being infections and infestations including sepsis.
oOne patient died 14 days after the last dose of study drug (within the 30-day reporting period) due to sepsis that was not related to study drug.
·Consistent with previous studies of SYN-004 in healthy volunteers, SYN-004 was not observed in blood samples from the majority of the evaluable patients.
oA total of 3 plasma samples (~2% of all analyzed samples) had low but quantifiable levels of SYN-004 using a sensitive ECL assay.
oNone of the 3 ECL positive plasma samples were found to contain active SYN-004 using a functional enzyme activity assay.
·Meropenem pharmacokinetics were as expected for this patient population.

 

Based on a review of the safety and pharmacokinetic data, the DSMC has recommended that the study may proceed to enroll Cohort 2 in which study drug (SYN-004 or Placebo) will be administered in combination with the IV beta-lactam antibiotic piperacillin/tazobactam.

 

Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics, commented, “These encouraging data support the clinical advancement of SYN-004 and build on the growing data that underscore its therapeutic potential. We remain on track to initiate the second cohort in Q4 2022, which is designed to evaluate the combination of SYN-004 with piperacillin/tazobactam. We are very grateful for the tremendous support from Dr. Dubberke and his team at Washington University as we take critical steps with the goal of improving standard treatment for these highly susceptible patients by overcoming existing limitations of broad-spectrum IV beta-lactam antibiotics.”

 

 

 

 

 

 

About the Phase 1b/2a Clinical Trial

 

The ongoing randomized, double-blinded, placebo-controlled Phase 1b/2a clinical trial is being conducted at Washington University School of Medicine in St. Louis. The trial is designed to evaluate the safety, tolerability, and potential absorption of oral SYN-004 (150 mg q.i.d. for a maximum of 28 days) into the systemic circulation of allogeneic HCT recipients who receive an IV antibiotic to treat fever. To mitigate risk, Cohort 1 of the study administered meropenem as the study-assigned antibiotic. Meropenem is a carbapenem antibiotic that is not metabolized by SYN-004. Patients in Cohorts 2 and 3 will be administered piperacillin/tazobactam and cefepime respectively, each of which can be metabolized by SYN-004. The trial is also designed to evaluate potential protective effects of SYN-004 on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 in allogeneic HCT recipients. The trial is expected to enroll up to 36 participants with three sequential cohorts, each evaluating a different study-assigned IV beta-lactam antibiotic. Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety Monitoring Committee that will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic. More information on the study is available here (NCT04692181).

 

About SYN-004 (ribaxamase)

 

SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection following conditioning therapy. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients may lead to adverse outcomes including CDI, VRE colonization and potentially fatal bacteremia and aGVHD. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients who received SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE.

 

About Synthetic Biologics, Inc.

 

Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com. 

 

 

 

 

 

 

Forward-Looking Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the encouraging data supporting the clinical advancement of SYN-004 and building on the growing data that underscore its therapeutic potential, remaining on track to initiate the second cohort in Q4 2022, which is designed to evaluate the combination of SYN-004 with piperacillin/tazobactam, SYN-004 improving standard treatment for the highly susceptible patients by overcoming existing limitations of broad-spectrum IV beta-lactam antibiotics, the potential protective effects of SYN-004 on the gut microbiome and generating preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 in allogeneic HCT recipients and the trial enrolling up to 36 participants with three sequential cohorts, each evaluating a different study-assigned IV beta-lactam antibiotic. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of SYN-004 to improve standard treatment for the highly susceptible patients by overcoming existing limitations of broad-spectrum IV beta-lactam antibiotics, the ability to enroll the anticipated number of patients in the Phase 1b/2a clinical trial, Synthetic Biologics' ability to reach clinical milestones when anticipated, Synthetic Biologics' ability to successfully combine and operate the business of Synthetic Biologics and VCN, Synthetic Biologics' and VCN's product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics' and VCN's ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of Synthetic Biologics' and VCN's products, developments by competitors that render such products obsolete or non-competitive, Synthetic Biologics' and VCN's ability to maintain license agreements, the continued maintenance and growth of Synthetic Biologics' and VCN's patent estate, the ability to continue to remain well financed, and other factors described in Synthetic Biologics' Annual Report on Form 10-K for the year ended December 31, 2021 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

 

 

 

 

 

 

For further information, please contact:

 

Investor Relations:

 

Chris Calabrese

 

LifeSci Advisors, LLC

 

ccalabrese@lifesciadvisors.com

 

917-680-5608

 

 

 

 EX-101.SCH 3 syn-20220927.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syn-20220927_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 syn-20220927_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2226615d1_ex99-1img001.jpg GRAPHIC begin 644 tm2226615d1_ex99-1img001.jpg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�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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 27, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 27, 2022
Entity File Number 001-12584
Entity Registrant Name SYNTHETIC BIOLOGICS, INC.
Entity Central Index Key 0000894158
Entity Tax Identification Number 13-3808303
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9605 Medical Center Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 417-4364
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol SYN
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 tm2226615d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000894158 2022-09-27 2022-09-27 iso4217:USD shares iso4217:USD shares 0000894158 false 8-K 2022-09-27 SYNTHETIC BIOLOGICS, INC. NV 001-12584 13-3808303 9605 Medical Center Drive Suite 270 Rockville MD 20850 301 417-4364 false false false false Common stock, par value $0.001 per share SYN NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://syntheticbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2226615d1_8k.htm syn-20220927.xsd syn-20220927_lab.xml syn-20220927_pre.xml tm2226615d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2226615d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2226615d1_8k.htm" ] }, "labelLink": { "local": [ "syn-20220927_lab.xml" ] }, "presentationLink": { "local": [ "syn-20220927_pre.xml" ] }, "schema": { "local": [ "syn-20220927.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "syn", "nsuri": "http://syntheticbiologics.com/20220927", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2226615d1_8k.htm", "contextRef": "From2022-09-27to2022-09-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://syntheticbiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2226615d1_8k.htm", "contextRef": "From2022-09-27to2022-09-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-103155-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-103155-xbrl.zip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end